生物制药创新失败药物挽救路径研究及其管理启示

Study on the rescued paths of failed biopharmaceutical drug innovation and its revelation

摘要:

本文以生物制药产业为背景,采取案例研究方法,瞄准沙利度胺、伟哥等四种经历失败重获新生的创新药物为研究对象,回溯其“失败—成功”的重生过程,抽象归纳了“科学家(大学、科研院所)—大企业合作—核心公司”、“科学家(专家型公司)—核心公司—专家型公司逐步内化为核心公司”及“科学家(核心公司)—核心公司全面行动”三种典型挽救路径,进而针对生物制药创新各方及失败药物挽救各参与方提出多种管理启示。

Abstract:

Under the background of biotechnology pharmaceutical industries, the paper takes a case study method, aiming at four kinds of innovative drugs that have failed to regenerate, such as thalidomide and Viagra, backtracking the rebirth process of "failure and success", and abstractly summed up "Scientists (universities, scientific research institutes) - big enterprise cooperation - Core Company", "scientist (Expert Company) - Core Company - expert company is gradually internalized into Core Company "and" scientist (Core Company) – its comprehensive action "three typical rescue paths. At last, multiple management revelations for all parties involved in biopharmaceutical innovation and failed drug recovery were put forward.